FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3177866008> ?p ?o ?g. }

• W3177866008 endingPage "899" @default.
• W3177866008 startingPage "893" @default.
• W3177866008 abstract "Aims: The aim of this study was to estimate the cost-effectiveness of nivolumab versus everolimus for second-line treatment of renal cell carcinoma (RCC) based on mature data, updated safety and decreased everolimus price.Materials and methods: A 3-state (pre-progression/progression-free disease, progressive disease and death) Markov model was developed from the perspective of the Australian health care system. Two scenarios were tested. Scenario 1 used 30-months clinical data and scenario 2 used updated 80-months clinical data with updated everolimus price. Inputs for quality-of-life and costs were informed by the literature and government sources. Incremental cost-effectiveness ratio (ICER) per quality adjusted life years (QALY) gained was reported and an ICER threshold of AU$75,000 was assumed. Threshold analysis was performed, and uncertainty was explored using one-way and probabilistic sensitivity analyses.Results: In scenario 1, the model estimated 1.73 QALYs at a cost of AU$105,000 for nivolumab and 1.48 QALYs at AU$38,000 for everolimus with an ICER = AU$266,871/QALY gained. A rebate of 54.4% was needed for nivolumab to reach the ICER threshold. For scenario 2, 1.93 QALYs at AU$111,418 was estimated for nivolumab and 1.60 QALYs at AU$31,942 for everolimus with an ICER of AU$213,320/QALY gained. The rebate needed to reach the ICER threshold was 54.9%. One-way sensitivity analyses for both scenarios showed that the cost of nivolumab, time horizon and utilities were main drivers. The cost-effectiveness acceptability curves highlighted the differences in cost-effectiveness of the two scenarios, as well as significant uncertainty in the results.Conclusions: A 54% rebate of the published price is needed for nivolumab to be cost-effective in Australia for the treatment of RCC. At that rebate, nivolumab remains cost-effective despite severe price erosion of everolimus because of improved longer term follow-up data. We recommend that generic price erosion should be accounted for when performing cost-effectiveness analysis." @default.
• W3177866008 created "2021-07-19" @default.
• W3177866008 creator A5042141112 @default.
• W3177866008 creator A5082663721 @default.
• W3177866008 creator A5090549280 @default.
• W3177866008 date "2021-01-01" @default.
• W3177866008 modified "2023-09-23" @default.
• W3177866008 title "Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price" @default.
• W3177866008 cites W1982967337 @default.
• W3177866008 cites W1993655814 @default.
• W3177866008 cites W2005295931 @default.
• W3177866008 cites W2022007357 @default.
• W3177866008 cites W2061161689 @default.
• W3177866008 cites W2083378657 @default.
• W3177866008 cites W2222086386 @default.
• W3177866008 cites W2325503488 @default.
• W3177866008 cites W2415125269 @default.
• W3177866008 cites W2567289819 @default.
• W3177866008 cites W2751965733 @default.
• W3177866008 cites W2765140973 @default.
• W3177866008 cites W3042347895 @default.
• W3177866008 cites W3120455542 @default.
• W3177866008 cites W2167593269 @default.
• W3177866008 doi "https://doi.org/10.1080/13696998.2021.1955540" @default.
• W3177866008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34259119" @default.
• W3177866008 hasPublicationYear "2021" @default.
• W3177866008 type Work @default.
• W3177866008 sameAs 3177866008 @default.
• W3177866008 citedByCount "1" @default.
• W3177866008 countsByYear W31778660082022 @default.
• W3177866008 crossrefType "journal-article" @default.
• W3177866008 hasAuthorship W3177866008A5042141112 @default.
• W3177866008 hasAuthorship W3177866008A5082663721 @default.
• W3177866008 hasAuthorship W3177866008A5090549280 @default.
• W3177866008 hasBestOaLocation W31778660081 @default.
• W3177866008 hasConcept C121608353 @default.
• W3177866008 hasConcept C126322002 @default.
• W3177866008 hasConcept C126894567 @default.
• W3177866008 hasConcept C143998085 @default.
• W3177866008 hasConcept C177713679 @default.
• W3177866008 hasConcept C2777472916 @default.
• W3177866008 hasConcept C2777701055 @default.
• W3177866008 hasConcept C2780030458 @default.
• W3177866008 hasConcept C3019894029 @default.
• W3177866008 hasConcept C71924100 @default.
• W3177866008 hasConceptScore W3177866008C121608353 @default.
• W3177866008 hasConceptScore W3177866008C126322002 @default.
• W3177866008 hasConceptScore W3177866008C126894567 @default.
• W3177866008 hasConceptScore W3177866008C143998085 @default.
• W3177866008 hasConceptScore W3177866008C177713679 @default.
• W3177866008 hasConceptScore W3177866008C2777472916 @default.
• W3177866008 hasConceptScore W3177866008C2777701055 @default.
• W3177866008 hasConceptScore W3177866008C2780030458 @default.
• W3177866008 hasConceptScore W3177866008C3019894029 @default.
• W3177866008 hasConceptScore W3177866008C71924100 @default.
• W3177866008 hasIssue "1" @default.
• W3177866008 hasLocation W31778660081 @default.
• W3177866008 hasLocation W31778660082 @default.
• W3177866008 hasOpenAccess W3177866008 @default.
• W3177866008 hasPrimaryLocation W31778660081 @default.
• W3177866008 hasRelatedWork W2784136589 @default.
• W3177866008 hasRelatedWork W2792841998 @default.
• W3177866008 hasRelatedWork W2969738919 @default.
• W3177866008 hasRelatedWork W2995003073 @default.
• W3177866008 hasRelatedWork W3216520672 @default.
• W3177866008 hasRelatedWork W4220793803 @default.
• W3177866008 hasRelatedWork W4252306764 @default.
• W3177866008 hasRelatedWork W4285598862 @default.
• W3177866008 hasRelatedWork W4309506371 @default.
• W3177866008 hasRelatedWork W4310754081 @default.
• W3177866008 hasVolume "24" @default.
• W3177866008 isParatext "false" @default.
• W3177866008 isRetracted "false" @default.
• W3177866008 magId "3177866008" @default.
• W3177866008 workType "article" @default.